Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis in a Real World Setting in the US (Bionaive Secukinumab Users NVS 521)

NCT05513014 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05513014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05513014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis in a Real World Setting in the US (Bionaive Secukinumab Users NVS 521)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
March 21, 2021
Completion date
August 31, 2021
Enrollment
1,518 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis